1. Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
- Author
-
Lustig Y, Barda N, Weiss-Ottolenghi Y, Indenbaum V, Margalit I, Asraf K, Doolman R, Chalkias S, Das R, Elfatarany G, Harats D, Kreiss Y, and Regev-Yochay G
- Subjects
- Humans, Female, Male, Middle Aged, Adult, mRNA Vaccines immunology, Immunoglobulin G blood, Immunoglobulin G immunology, Spike Glycoprotein, Coronavirus immunology, Spike Glycoprotein, Coronavirus genetics, Aged, Vaccines, Synthetic immunology, Vaccines, Synthetic administration & dosage, Immunogenicity, Vaccine, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, Antibodies, Viral blood, Antibodies, Viral immunology, COVID-19 prevention & control, COVID-19 immunology, SARS-CoV-2 immunology, SARS-CoV-2 genetics, Immunity, Humoral
- Abstract
JN.1, the dominating SARS-CoV-2 variant, is antigenically distinct from ancestral BA.1, BA.5 and XBB.1.5 variants, raising concern about effectiveness of updated COVID-19 vaccines. Here, we compared the neutralizing antibody response against JN.1, 1-month after receipt of the three available Moderna mRNA vaccines. Sera obtained from 37, 30 and 30 XBB.1.5, BA.1 and BA.4-5 -vaccine recipients, respectively, were tested for anti-RBD IgG and for JN-1 specific neutralizing antibody levels. Geometric mean fold rise (GMFR) in JN.1 specific neutralizing titers was 27 (95 % CI: 17-43.1), 10.1 (95 % CI: 6.48-15.7) and 8.77 (95 % CI: 5.69-13.5) following XBB.1.5, BA.1 and BA.4-5 vaccines, respectively, translating into a 64 % lower adjusted response (geometric mean ratio [GMR] = 0.36, 95 % CI: 0.21-0.6) in the BA.1 arm, and a 75 % lower response (GMR = 0.25, 95 % CI: 0.15-0.43) in the BA.4-5 arm. This suggests that XBB.1.5 vaccination will most likely, result in improved effectiveness against JN.1 compared with other COVID-19 vaccines., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Spyros Chalkias, Rituparna Das and Gamal Elfatarany are employees of Moderna, Inc. and may hold stock/stock options in the company. Gili Regev-Yochay served as a consultant to Merck, GSK, Astrazenca, Pfizer and Moderna., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF